7/19/2019  7:52:31 PM Chg. +8.300 Volume Bid7:59:56 PM Ask7:59:56 PM Market Capitalization Dividend Y. P/E Ratio
162.650EUR +5.38% 96
Turnover: 15,087
162.800Bid Size: 50 164.200Ask Size: 50 8.39 bill.EUR 0.00% -

Business description

Galapagos N.V. is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Their pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. Galapagos’ mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary cells and patient cells, the company discovers which proteins (‘targets’) play a key role in causing diseases such as rheumatoid arthritis, inflammatory bowel disease and fibrosis. Galapagos then aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease. This approach addresses the root cause of the disease rather than just treating the symptoms. The Galapagos group, including fee-for-service subsidiairy Fidelta, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France and Croatia.
 

Management board & Supervisory board

CEO
Onno van de Stolpe
Management board
Bart Filius, Dr. Andre Hoekema, Dr. Piet Wigerinck, Walid Abi-Saab, M.D.
Supervisory board
Raj Parekh, Dr. Christine Mummery, Dr. Mary Kerr, Dr. Werner Cautreels, Howard Rowe, Katrine Bosley, Onno van de Stolpe
 

Company data

Name: Galapagos N.V.
Address: Generaal De Wittelaan L11 A3,BE-2800 Mechelen
Phone: +32-15-342900
Fax: +32-15-342901
E-mail: rd@glpg.com
Internet: www.glpg.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 62.41%
IPO date: -

Investor relations

Name: Elizabeth Goodwin
IR phone: -
IR Fax: -
IR e-mail: ir@glpg.com

Company calendar

CW 30 | 7/25/2019 Interim Report 2nd Quarter/6 Months
CW 43 | 10/24/2019 Interim Report 3rd Quarter/9 Months
CW 8 | 2/20/2020 4th Quarter/Annual Report
 

Main Shareholders

Freefloat
 
62.41%
Gilead
 
22.00%
Van Herk Investment
 
9.91%
Sands Capital Management LLC
 
5.68%